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Background: Lack of appropriate reporting of methodological details has previously been shown to distort risk of
bias assessments in randomized controlled trials. The same might be true for observational studies. The goal of
this study was to compare the Newcastle-Ottawa Scale (NOS) assessment for risk of bias between reviewers and
authors of cohort studies included in a published systematic review on risk factors for severe outcomes in patients
infected with influenza.
Methods: Cohort studies included in the systematic review and published between 2008–2011 were included. The
corresponding or first authors completed a survey covering all NOS items. Results were compared with the NOS
assessment applied by reviewers of the systematic review. Inter-rater reliability was calculated using kappa (K) statistics.
Results: Authors of 65/182 (36%) studies completed the survey. The overall NOS score was significantly higher (p < 0.001)
in the reviewers’ assessment (median = 6; interquartile range [IQR] 6–6) compared with those by authors (median = 5, IQR
4–6). Inter-rater reliability by item ranged from slight (K = 0.15, 95% confidence interval [CI] = −0.19, 0.48) to poor
(K = −0.06, 95% CI = −0.22, 0.10). Reliability for the overall score was poor (K = −0.004, 95% CI =−0.11, 0.11).
Conclusions: Differences in assessment and low agreement between reviewers and authors suggest the need to contact
authors for information not published in studies when applying the NOS in systematic reviews.
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One of the most important aspects of systematic reviews
is the assessment of the risk of bias of included studies
[1]. Evaluating the reliability and validity of risk of bias
assessment scores can help generate better assessment
tools. The Newcastle-Ottawa Scale (NOS) is a risk of
bias assessment tool for observational studies that is rec-
ommended by the Cochrane Collaboration [1,2]. Some
characteristics of this tool have been assessed, such as
inter-rater reliability, which has been variable ranging
from fair to high depending on the types of observa-
tional studies assessed and the raters [3,4]. In addition to
the potentially limited inter-rater reliability, lack of
reporting of methodological details in published articles* Correspondence: loebm@mcmaster.ca
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unless otherwise stated.may potentially distort the risk of bias assessment as it
was shown for randomized controlled trials (RCT) [5,6].
The objectives of our study were therefore to compare
the NOS assessment between reviewers with access to the
publications only and the authors of published studies,
using the list of studies included in a recently published
systematic review of observational studies on risk factors
to predict severe outcomes in patients with influenza [7].
We hypothesized that reviewers in the systematic review
who had to rely on the published information would have
assigned lower NOS scores (i.e., greater risk of bias) com-
pared with its authors, and that the agreement between
authors and reviewers would be marginal.Methods
Eligibility criteria
Authors of studies included in a published systematic re-
view on risk factors for severe outcomes in patients with
influenza and published between 2008 and 2011 were in-
cluded [7]. More remote publications were not considered,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Distribution of total scores for the Newcastle-Ottawa
Scale (NOS) for cohort studies. Reviewers (left) and authors (right)
evaluated for risk of bias for cohort studies (n = 65).
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curate and authors may not recall details of their studies.
Quality assessment: NOS and NOS-derived survey
The NOS assigns up to a maximum of nine points for the
least risk of bias in three domains: 1) selection of study
groups (four points); 2) comparability of groups (two
points); and 3) ascertainment of exposure and outcomes
(three points) for case–control and cohort studies, re-
spectively (Additional file 1) [2]. Survey questions were de-
veloped based on the NOS’ questions covering all three
domains so that authors could provide detailed informa-
tion about their studies. Because the NOS questionnaires
are slightly different between case–control and cohort
studies, two surveys were created.
Vaccination status for influenza and antiviral treat-
ment were defined as the most important covariates
that defined comparability, consistent with the NOS as-
sessment conducted by the reviewers in the systematic
review [7].
The corresponding author and the first author were
contacted by email and were provided with the link to the
actual electronic survey. An online survey was provided to
all authors where their name, responses and timestamp
were securely documented. Authors were required to re-
spond to all questions provided prior to submission and
answered follow-up questions only when prompted to. An
example of a follow-up question: For ascertainment of ex-
posure, authors who claimed using structured interviews
had to also report whether the interviewers were blinded
to exposure status. A feedback form was provided at the
end of the survey for authors to comment on the survey.
A total of two reminders were sent to authors not com-
pleting the survey.
Analysis
Questions in the survey were matched to the original
NOS items, so that points were awarded to the respect-
ive answers.
Differences in the NOS scores between the reviewers’
and authors’ assessment were compared with the Wilcoxon
paired sign-rank test.
Inter-rater agreement Cohen’s kappa was used to com-
pare agreement between the reviewers from the systematic
review and the authors’ assessments. The scores were com-
pared between raters across each NOS domain or item.
Weighted kappa was performed for variables with more
than two classifications (i.e., comparability had scores of 0,
1, and 2). A weighted kappa was also performed for the
total NOS scores.
Agreement interpretation was based on established
categorizations: poor (K < 0.00), slight (0.00-0.20), fair
(0.21-0.40), moderate (0.41-0.60), substantial (0.61-0.80),
and almost perfect (0.81-1.00) [8].MedCalc® was used for all weighted/non-weighted kappa
analyses [9,10] and for the Wilcoxon paired sign-rank test.
Mean and standard deviation (SD), median and interquar-
tile range (IQR) were reported.
Results
Of the 239 studies included in the systematic review,
196 studies (82%; 6 case–control and 190 cohort studies)
met the inclusion criteria for this study (i.e., published
from 2008 to 2011). Six cohort studies were excluded, as
there was no information on contacting authors (three
articles published by the World Health Organization
(WHO) and three articles by Centre for Disease Control
and Prevention (CDC)). An additional two studies were
excluded, as contacting authors could not be identified.
Authors of 65/182 (36%) eligible cohort studies and
2/6 (33%) case–control studies completed the survey
(Additional files 2 and 3). Given the sparse data on case–
control studies, these studies were excluded from analysis.
Reviewer assessment was similar for included (n = 65,
mean NOS score = 5.85, median = 6, IQR 6–6) and ex-
cluded studies (n = 117, mean = 5.81, median = 6, IQR 5–6).
The distribution of NOS scores by reviewers and authors
for cohort studies included in this analysis is shown in
Figure 1. The risk of bias by the study authors was felt to
be higher, with a lower average NOS score (mean = 4.85,
SD = 1.19, median = 5, IQR 4–6) compared with the NOS
reviewers (mean = 5.85, SD = 0.94, median = 6, IQR 6–6).
The difference was statistically significant (p < 0.001,
Wilcoxon paired signed-rank test). Thirty (46%) out of
the 65 cohort studies had overall NOS scores that were
two or more points apart, of which 27 studies had re-
viewers scoring two or more points higher (i.e., lower
risk of bias) than authors (Figure 2). Eight and one of
these 30 studies reviewers scored three and four points
higher than authors, respectively.
Figure 2 Differences in Newcastle-Ottawa Scale (NOS) total
score between reviewers and authors. The total score assigned
for each cohort study by reviewers was subtracted with the total
score assigned by authors.
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the NOS items is presented in Table 1. Reliability was slight
(i.e., K of 0.00 to 0.15) for the majority of items (representa-
tiveness of the exposed cohort, selection of the non-exposed
cohort, demonstration that outcome of interest was not
present at the start of study, comparability of cohorts, and
adequacy of follow-up of cohorts). The items ascertainment
of exposure, assessment of outcome, and “was follow-up long
enough for outcomes to occur” had poor reliability (i.e., K
of −0.06 to −0.02). Reliability for the total NOS score was
poor (K=−0.004, 95% confidence interval [CI] = −0.11, 0.11).
A second inter-rater reliability test was performed using
weighted kappa (K) comparing total NOS scores catego-
rized into three groups: very high risk of bias (0 to 3 NOS
points), high risk of bias (4 to 6), and low risk of bias




Representativeness of the exposed cohort 0.03 (−0.10, 0.15)
Selection of the non-exposed cohort 0.00 (0.00, 0.00)
Ascertainment of exposure −0.02 (−0.08, 0.04)
Demonstration that outcome of interest
was not present at start of study
0.09 (−0.16, 0.35)
Comparability 0.00a (−0.11, 0.12)
Assessment of outcome −0.04 (−0.09, 0.00)
Was follow-up long enough for
outcomes to occur
−0.06 (−0.22, 0.10)
Adequacy of follow-up of cohorts 0.15 (−0.19, 0.48)
Total NOS score −0.004a (−0.11, 0.11)
Total categorized NOS score 0.14b (−0.02, 0.29)
Abbreviation: 95% CI = 95% confidence interval.
aLinear weighted kappa was used for both Comparability and Total NOS score; other
bQuadratic weighted kappa was used assuming the difference between very high r
cNumber of studies with a 0, ±1, or more than ±2 points difference between review“very high risk” vs. “high risk” and “high risk” vs. “low
risk” were treated as comparably different. Reliability for
the categorized total NOS score was slight (K = 0.14, 95%
CI =−0.02, 0.29; Table 1). Compared with the poor agree-
ment from the initial inter-rater reliability test, the categorized
NOS score showed better but still only slight agreement.
Discussion
By comparing overall scores and inter-rater reliability of
the NOS quality assessment tool between reviewers and
authors, we found remarkably low inter-rater reliability.
The majority of the cohort studies were rated as being at
higher risk of bias by authors than by reviewers. That is,
the reviewers assigned higher NOS scores by two or more
points of a total of nine points for the overall NOS score.
Inter-rater reliability between authors and reviewers was
remarkably low and the agreement across items was only
minimal. The item about adequacy of follow-up of cohorts
had the highest kappa value of 0.15 (95% CI = −0.19,
0.48), despite being considered only as slight agreement.
The comparably small room for subjectivity might explain
the relatively high kappa value given that the authors sim-
ply had to indicate whether or not there was loss to
follow-up for their cohort, and whether it would poten-
tially have introduced bias into their study. The overall
lack of agreement between reviewers and authors persisted
even after performing a second inter-rater reliability test
when categorizing into three groups of risk of bias. Of
note, the difference in NOS scores was 2 or higher in al-
most half of the studies. While one may argue that a one
point difference would not have any practical implications,
a two point difference would likely be regarded as clinic-
ally important given that this would reflect a >20% (i.e., 2/
9 points) difference in the assessment.NOS) assessments, by item






Slight 43 (66.2%) 22 (33.8%) 0 (0%)
Slight 53 (81.5%) 12 (18.5%) 0 (0%)
Poor 12 (18.5%) 53 (81.5%) 0 (0%)
Slight 47 (72.3%) 18 (27.7%) 0 (0%)
Slight 38 (58.5%) 18 (27.7%) 9 (13.8%)
Poor 59 (90.8%) 6 (9.2%) 0 (0%)
Poor 31 (47.7%) 34 (52.3%) 0 (0%)
Slight 57 (87.7%) 8 (12.3%) 0 (0%)
Poor 15 (23.1%) 20 (30.8%) 30 (46.1%)
Slight 44 (67.7%) 21 (32.3%) 0 (0%)
kappas were not weighted (i.e., Cohen’s kappa was applied).
isk, high risk and low risk were comparably unequal.
er and author assessments, separated by item.
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the reviewers may not have had all information needed
available from the published article in order to assess the
risk of bias reliably. For example, when evaluating repre-
sentativeness of exposed cohort reviewers may treat the
study population as truly representative, but the author
knew that the study group was not representative for the
average population in the respective setting.
Methodological studies have found that reviewers may
overestimate the risk of bias of randomized controlled tri-
als due to unclear or lacking details from insufficient
reporting by authors [5,6]. In one of these studies involv-
ing 98 RCTs, 55% failed to report allocation concealment
and from 25% to 96% did not report blinding status (e.g.,
for participants, data analysts) [5]. However, once authors
were contacted, it was noted that appropriate concealment
and blinding were in fact in place in many of these studies
[5]. In other words, reviewers without the unpublished de-
tails from authors would have overestimated the risk of
bias for RCTs, contrary to our findings when using NOS
for observational studies. One possible explanation might
be that NOS allows for more subjectivity than when asses-
sing RCTs; lack of information in RCTs automatically re-
sults in higher risk of bias, whereas NOS requires the
reviewer to decide subjectively on the risk of bias for each
item based on the information available in the report.
Others have also found the NOS tool’s decision rules and
guidelines to be vague and difficult to use [3]. For ex-
ample, the difference between a “structured interview” and
“written self-report” was difficult to determine if the study
used a structured validated survey that was completed in-
dependently by study participants [3]. Similar ambiguity
was found in our investigation for the item ascertainment
of exposure, where NOS reviewers identified 59 of the
65 cohort studies using secure records (i.e., one point
assigned). In contrast, 44 out of the 65 authors claimed to
be using medical records (i.e., no points assigned).
Inter-rater reliability
The developers of the NOS evaluated the tool for face and
criterion validity by comparing it with an established scale
by Downs and Black [11]. Ten cohort and 10 case–control
studies about the association between breast cancer and
hormone replacement therapy were examined. Criterion
validity showed strong and moderate agreement for cohort
(intra-class correlation coefficient [ICC] = 0.88) and case–
control studies (ICC = 0.62), respectively. Inter-rater reli-
ability was also high for both cohort (ICC = 0.94) and
case–control studies (ICC = 0.82).
To our knowledge, only two other studies have exam-
ined inter-rater reliability of NOS other than those con-
ducted by the developers of the tool [3,4]. Contrary to
findings from developers of the tool, other studies have
found overall low inter-rater reliability. In a study byHartling [3], two reviewers applied NOS to 131 cohort
studies included in eight meta-analyses on different med-
ical topics. Inter-rater reliability between reviewers ranged
from poor (K = −0.06, 95% CI = −0.20, 0.07) to substantial
(K = 0.68, 95% CI = 0.47, 0.89), although eight out of nine
of the NOS items had K values <0.50 [3]. Reliability for
overall NOS score was fair (K = 0.29, 95% CI = 0.10, 0.47).
A similar lack of agreement was found in a study applying
the NOS to observational studies on cognitive impairment
following electroconvulsive therapy for major depressive
disorders [4]. Using inexperienced student raters, inter-
rater reliability for cohort studies ranged from K = −0.14
(95% CI = −0.28, 0.00) to K = 0.39 (95% CI = −0.02,
0.81), and for case–control studies from K = −0.20 (95%
CI = −0.49, 0.09) to K = 1.00 (95% CI = 1.00, 1.00). All
nine of the NOS items and seven out of nine items had
K values <0.50 for cohort and case–control studies, re-
spectively. However, the findings of the latter study may
also explain to some extent the disagreement between
methodically trained reviewers and authors of study: In
our study, the disagreement between raters may also
have been attributable to the authors’ lack of experience
applying the NOS.
Limitations
One limitation of our study was the relatively small sample
size of 65 cohort studies. With a response rate of 36%, se-
lection bias may be present as authors who responded to
the survey might have a different level of expertise and
interest in research methodology than non-responders.
Also, all studies included were from one field of medicine.
Notably however, the reviewer assessments of the risk of
bias were similar for the included and excluded studies. It
remains unclear whether the difference between the re-
viewer and author’s assessments were due to different in-
formation available to them for assessment, or whether
authors’ lack of familiarity with the NOS tool resulted in
this finding. Given that the one item (i.e., representative-
ness of the exposed cohort) that would not need to be
downgraded based on lack of information was similarly
low in agreement as items that would expect downgrading
for lack of reporting, subjective interpretation was prob-
ably the primary driver resulting in the low agreement be-
tween reviewers and authors. This would emphasize, as
suggested by Hartling [3] and Oremus [4], that training
and detailed guidance is needed in order to appropriately
apply the NOS. Although the survey explained in detail
how the assessment should be conducted, lack of familiar-
ity with the NOS tool by the authors may have negatively
affected their performance.
Another limitation is the nature of the inter-rater reliabil-
ity test, that is, some have considered kappa to be an overly
conservative measure of agreement [12]. Since the kappa
value depends on the observed categories’ frequencies, the
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ample was the item selection of the non-exposed cohort,
where 82% of the time both reviewers and authors agreed
that the non-exposed were derived from the same popula-
tion as the exposed (i.e., one point assigned). However,
there were no occurrences where both raters agreed that
the non-exposed were not derived from the same popula-
tion as the exposed, which resulted in an underestimation
of the agreement. A larger sample of studies may have
circumvented this problem.
Conclusions
It remains unclear whether the difference between the re-
viewer and authors’ assessment and low inter-rater reliabil-
ity was due to lack of information available to reviewers in
published influenza papers, or whether it was the authors’
lack of familiarity with the NOS items. However, it is pru-
dent to conclude that systematic reviewers should contact
authors for information not published in the study to sup-
plement the use of the risk of bias assessment tool. The
room for subjectivity in the NOS tool may have negatively
affected inter-rater reliability. Revised or new instruments
using less subjective items may improve inter-rater reliabil-
ity and potentially validity of the risk of bias assessment of
observational studies in systematic review.
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Additional file 1: Original NOS and survey questions for cohort
studies. Original NOS (left) and survey questions (right) that were sent to
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Additional file 2: Cohort studies included in analysis. References of all
65 cohort studies who completed the survey and included in data analysis.
Additional file 3: Raw data for NOS reviewer and author
assessments. Risk of bias assessments of all 65 cohort studies by NOS
reviewers and authors. Scores were tabulated and separated by NOS
domain and item, with total scores included.
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